Generic Weight-Loss Drug Coming to Market
Prescription referral service PharmaGiant.com is expanding its affordable medication catalog to include a generic version of semaglutide. The move aims to increase access to the popular diabetes and weight-loss medication as U.S. drug costs continue to climb.
The active ingredient, semaglutide, is the powerhouse behind brand-name drugs Ozempic and Wegovy, manufactured by Novo Nordisk. The patents for these blockbuster drugs are set to expire at different times globally, with protections in the U.S. and Europe lasting until 2031-2032, while patents in other countries like China and India are expiring as early as 2026. Currently, what many refer to as "generic semaglutide" in the U.S. is actually a compounded version. Federal law allows compounding pharmacies to produce versions of a drug during a shortage, which has been the case for semaglutide. However, these compounded drugs are not the same as FDA-approved generics, which must undergo a rigorous review to ensure they are bioequivalent to the original. The cost difference is stark. Brand-name Ozempic and Wegovy can cost between $900 and $1,300 a month without insurance. Compounded versions are significantly cheaper, often ranging from $200 to $400 monthly. Historically, the introduction of a single FDA-approved generic drug can cut the brand-name price by about 39%, and with four or more competitors, prices can plummet by over 95%. Given the billions in revenue at stake, Novo Nordisk has actively defended its patents, filing lawsuits against compounding pharmacies, medical spas, and telehealth companies offering unapproved semaglutide. These legal actions allege patent infringement and false advertising, aiming to block the sale of "copycat" versions before official patent expiry. Several generic drug manufacturers are lining up to enter the market once patents expire. Companies like Viatris, Sun Pharma, and Dr. Reddy's Laboratories have already developed or filed applications for their own versions of semaglutide. In India alone, at least half a dozen firms are expected to launch generics immediately after the patent expires there in March 2026. To receive FDA approval, a generic drug manufacturer must submit an Abbreviated New Drug Application (ANDA). This process doesn't require repeating the original clinical trials but must prove the generic contains the identical active ingredient and works in the same way and in the same amount of time as the brand-name drug.
